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Objective: Despite the increased prevalences of hypertension, type 2 diabetes mellitus (T2DM),
hyperlipidemy, and obesity in patients with non-functioning adrenal adenomas (NFAAs), there is a
paucity of data on long-term atherosclerotic morbidity as well as the long-term cardiovascular effects of
adrenalectomy in these patients.
Design, patients, and methods: This retrospective study includes the results of baseline and follow-up
investigations of 125 patients (29 males and 96 females; mean age 60.1 years) with NFAAs referred for
endocrine evaluation between 1990 and 2001. Of the 125 patients, 47 underwent unilateral
adrenalectomy, while 78 patients were followed conservatively. These patients were reinvestigated after
a mean follow-up time of 9.1 (5–16) years in 2006, with special emphasis on laboratory and other
atherosclerotic risk factors (ARF), vascular events, and interventions.
Results: The prevalences of hypertension, impaired glucose tolerance or T2DM, hyperlipidemy, and
obesity were 82, 43, 58, and 50%, and 89, 58, 82, and 50% at baseline and follow-up, respectively.
None of the investigated ARF prevalences were different between patients treated and not treated with
adrenalectomy, and between patients with and without subclinical Cushing’s syndrome. The
prevalences of angina pectoris, acute myocardial infarction, coronary, and peripheral arterial
interventions or cerebrovascular stroke did not differ significantly between patients treated and not
treated with adrenalectomy.
Conclusion: Our study confirms previous investigations reporting markedly increased prevalences of
various ARF in patients with NFAAs. Adrenalectomy performed in these patients failed to decrease the
prevalence of ARF and atherosclerotic morbidity.
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Adrenal incidentalomas are mostly (in 70–80% of cases)
non-functioning adrenal adenomas (NFAAs) which do
not cause classical clinical signs and symptoms of
hormone excess syndromes (1–4). However, 5–47% of
the NFAAs show mild cortisol oversecretion without
symptoms of Cushing’s syndrome referred to as sub-
clinical autonomous glucocorticoid hypersecretion or
subclinical Cushing’s syndrome. The prevalence of
subclinical Cushing’s syndrome among patients with
NFAAs depends on the criteria used to define it. The lack
of a golden standard, however, makes the diagnosis of
subclinical hypercortisolism uncertain (3, 5–14).
Several lines of evidence suggest that in addition to
cortisol-producing adrenal adenomas causing overt
Cushing’s syndrome, NFAAs are also associated withndocrinologyan increased atherosclerotic risk (15). The increased
prevalence of various biochemical disturbances and
accompanying diseases such as type 2 diabetes (T2DM)
and hypertension is thought to be resulted from a mild
glucocorticoid overactivity of these tumors. Unfortu-
nately, this mild glucocorticoid excess cannot be always
detected with a sufficient degree of sensitivity and
specificity.
Autonomous cortisol hypersecretion may cause a
variety of metabolic derangements and disorders, such
as arterial hypertension, impaired glucose tolerance
(IGT) and T2DM, hypercholesterolemia, hypertriglicer-
idemia, hyperuricemia, and obesity. An increased
prevalence of these metabolic disorders has been
reported in patients with subclinical Cushing’s syn-
drome (16–24). Mild autonomous cortisol hypersecre-
tion caused by seemingly silent adrenal adenomas hasDOI: 10.1530/EJE-08-0707
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syndrome (16, 25, 26).
These metabolic disorders are well-known risk factors
for atherosclerosis. It was shown that surgical treat-
ment of endogenous hypercortisolism reduces mortality
and morbidity (18, 21, 27, 28). However, there is a lack
of long-term follow-up studies that investigate the issue
of whether patients with incidentally discovered adrenal
adenomas, either hormonally inactive or only moder-
ately active, could benefit from adrenalectomy in terms
of cardiovascular morbidity and mortality.
The aim of our present study was to investigate the
prevalence of various atherosclerotic risk factors (ARF),
both at baseline and at least 5 years later in patients
with NFAAs. Further aim of this work was to study
whether adrenal surgical intervention could have an
impact on atherosclerotic morbidity and mortality of
these patients.Subjects and methods
The results of clinical, laboratory, and imaging investi-
gations of patients with NFAAs referred for evaluation
to our endocrine unit at Semmelweis University
between 1990 and 2001 were retrospectively analyzed.
The initial imaging modalities were usually ultra-
sonography and computed tomography. All patients
underwent complete clinical, radiological, and hormo-
nal evaluation during their baseline investigation.
Serum cortisol concentrations were measured from
blood samples collected at 0800 and 2400 h, as well
as after a low-dose (1 mg) dexamethasone suppression
test. Hormonal investigations also included the
measurements of serum DHEA sulfate, aldosterone,
17-hydroxyprogesterone, testosterone, plasma ACTH
concentration, and plasma renin activity. The 24-h
urine collection was performed for the determination of
vanillylmandelic acid excretion. Nuclear magnetic
resonance imaging and cholesterol- or MIBG-scintigra-
phy were performed if indicated. In case of a suspicion
for primary aldosteronism, saline suppression test
and, in some patients, selective adrenal vein sampling
for aldosterone and cortisol measurements were also
performed.
Based on the results of these investigations, patients
with classic hormone excess syndrome (primary
hyperaldosteronism, adrenal Cushing’s syndrome, and
pheochromocytoma) and those with a tumor greater
than 4 cm commonly underwent adrenal surgery.
Adrenal surgery was also performed if the possibility
of adrenal malignancy persisted even after repeated
laboratory and imaging investigations. Adrenal malig-
nancy was frequently suspected in patients with tumors
greater than 4 cm with irregular contours and a CT
attenuation value greater than 10 HU, or with inho-
mogenities suggesting intratumoral necrosis or hemor-
rhage. However, several patients with a tumor diameterwww.eje-online.orgsmaller than 4 cm were subjected to adrenalectomy
when CT or MRI morphology not unequivocally
suggested a benign lipid-rich adrenal lesion. In some
other cases with a tumor size smaller than 4 cm, the
patient expressed a strong preference for surgical
intervention, especially when laparoscopic operation
for symptomatic gallbladder stones offered the choice of
simultaneous laparoscopic adrenalectomy.
In 2006, 171 patients diagnosed with NFAAs
between 1990 and 2001 were invited in letter for an
ambulatory follow-up medical investigation. Of the 171
invited patients, 113 patients were re-examined using
our re-investigation protocol. Patients were instructed
to present all of the medical documents including the
results of all laboratory and imaging examinations and
hospitalization records. Our re-investigation protocol
consisted of a detailed medical and drug history,
physical examination including blood pressure, body
weight, and height measurements, as well as detailed
laboratory and basal hormone investigations. The
protocol was approved by the local ethics committee.
All of the patients with an abdominal CT performed 2 or
more years earlier underwent adrenal computed
tomography. The CT diagnosis of adrenal adenoma
was based on the following criteria: mass size usually
lower than 4 cm, homogeneity, regular well-defined
margins, and attenuation values less than 10 HU on
unenhanced CT and, when using a 10- to 15-min
delayed enhanced CT, a threshold value of 50–60% of
the initial enhancement (3). In addition, all of the
relevant medical documents of 12 further patients (four
patients treated and eight not treated with adrenalect-
omy), who could not attend our clinic for the follow-up
examination, were obtained either from the patients or
their relatives, and the data were subsequently verified
during a consultation with their family doctors. The
reasons for the non-attendance were hemiparesis
caused by ischemic cerebrovascular stroke (one
patient), severe chronic obstructive pulmonary disease
(one patient), and severe ischemic heart disease (one
patient), deaths from malignant non-adrenal tumors
(two patients), from severe chronic obstructive pulmon-
ary disease (one patient), from cardiovascular disease
(five patients), and from unknown cause (one patient).
Of the 125 patients with NFAAs having follow-up
examinations or presenting follow-up data, 47 patients
underwent unilateral adrenalectomy between 1990
and 2001. Histological examination revealed a benign
adrenocortical adenoma in each patient. The remaining
78 patients were treated conservatively, without
adrenalectomy. Of the 46 patients whose follow-up
data were not available, 15 patients had unilateral
adrenalectomy between 1990 and 2001 according to
earlier records. Baseline plasma cortisol concentrations
at 0800, 2400 h and after low-dose dexamethasone test
as well as tumor diameters were not different between
patients who were and were not available for follow-up
investigations.
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patients underwent fasting blood sampling for detailed
laboratory measurements including complete blood cell
count, hepatic and kidney functions, detailed lipopro-
tein, and hormone measurements. Patients on anti-
hyperlipidemic medications and those who had total
cholesterol greater than 5.2 mmol/l, low density
lipoprotein cholesterol greater than 2.6 mmol/l or
triglycerides greater than 1.7 mmol/l were considered
to have hyperlipidemia.
Patients with a previous definitive diagnosis of
diabetes mellitus and those on antidiabetic medications
were regarded as diabetic. All of the other patients
underwent an oral glucose tolerance test (OGTT, 75 g
glucose diluted in 250 ml water). IGT and diabetes
mellitus were defined according to the criteria of WHO
(1999) (29). Diabetes mellitus was diagnosed when
fasting plasma glucose exceeded 7.0 mmol/l or the
glucose response after OGTT at 120 min was
11.1 mmol/l or greater. IGT was diagnosed when blood
glucose levels at 120 min after OGTT were between 7.8
and 11.0 mmol/l. Laboratory results obtained during
the baseline in-hospital examination including fasting,
postprandial or after OGTT plasma glucose concen-
trations were reviewed and each patient was reclassified
as normal, having IGT or diabetes mellitus according to
the 1999 WHO criteria (29). Patients regularly taking
antihypertensive medications and patients repeatedly
having blood pressure greater than 140/90 mmHg were
considered to have hypertension (30).
Subclinical Cushing’s syndrome was diagnosed in
patients without overt clinical signs and symptoms of
Cushing’s disease with at least one of the following two
criteria: i) midnight serum cortisol concentration
greater than 5 mg/dl and ii) plasma cortisol
concentration greater than 3.6 mg/dl after low-dose
dexamethasone suppression test.
For the comparison of the prevalences of hyperten-
sion and diabetes mellitus in our patients to that of the
general Hungarian population, a large, community-
based sample obtained in primary care facilities in four
Hungarian counties was used. This database was shown
to broadly represent the Hungarian general population,
as virtually all Hungarian inhabitants are registered at
family doctors (31).Table 1 Main clinical characteristics of the 125 patients with non-fun
examination or presented follow-up data.
All patients
Patient
adrena
Number of patients 125 47
Male/female 29/96 8/39
Age of patients at baseline, year 51.8G9.9 50.6G7
Age of patients at follow-up, year 60.9G9.9 60.0G7
Baseline tumor diameter, mm 26.0G11.9 33.4G1
Follow-up time, year 9.1G3.1 9.4G3.
Data are given as means and SDs. NS, not significant.Statistical analysis
Statistical analysis was performed using Statistica
package (version 7.0, Statsoft Inc., Tulsa, Oklahoma,
USA). A value of P!0.05 was considered to be
significant. The relative frequencies of each athero-
sclerotic event and disease recorded at follow-up were
compared between patient groups treated with and
without adrenalectomy, using chi-square analysis and
Fisher’s exact test. The frequencies of metabolic
disorders and hormonal parameters were compared
with t-test and Mann–Whitney U-test.Results
The main clinical characteristics of the 125 patients
with NFAAs, who participated in the follow-up
examination or presented follow-up data are sum-
marized in Table 1. There were no statistically
significant differences in age and sex ratios between
patients treated and not treated with adrenalectomy.
The median follow-up time for all patients was 9.1 years
(range, 5–16 years), and patients with and without
adrenalectomy had similar follow-up times (Table 1).
However, the baseline diameter of adrenal tumors of
patients who underwent adrenalectomy was signi-
ficantly larger when compared with that found at
baseline in patients without subsequent adrenalectomy.
At the baseline endocrine investigation, plasma
cortisol concentrations at 0800 and 2400 h, as well
as after a low-dose dexamethasone test failed to show
differences between patients subsequently treated and
not treated with adrenalectomy (Table 2).
Table 3 shows the prevalences of various ARF in
patients with NFAAs both at baseline and at the follow-
up. The prevalences of risk factors and laboratory data
at the time of follow-up were compared with the
baseline data, and these parameters were also compared
in the two groups of patients treated and not treated
with adrenalectomy. As shown in Table 3, the
prevalences of hypertension at baseline were very high
in both groups (86 and 80% in patients with and
without subsequent adrenalectomy, respectively), and
this high prevalence persisted at the time of follow-upctioning adrenocortical adenomas who participated in the follow-up
s with
lectomy
Patients without
adrenalectomy
Difference between
patients with and
without adrenalectomy
78
21/57 NS
.2 52.5G11.2 NS
.1 61.4G11.3 NS
0.8 21.5G10.2 P!0.0001
6 8.8G2.8 NS
www.eje-online.org
Table 2 Baseline hormonal findings in patients with non-functioning adrenocortical adenomas subsequently treated and not treated with
adrenalectomy.
Patients with
subsequent adrenalectomy
Patients without
subsequent adrenalectomy
Difference between
patients with and without
adrenalectomy
Midnight plasma cortisol (mg/dl) 2.6G1.7 3.1G2.6 NS
Morning plasma cortisol (mg/dl) 9.8G5.8 10.9G4.6 NS
Plasma cortisol after low-dose
DXM (mg/dl)
2.2G2.4 1.9G0.7 NS
Plasma ACTH (pg/ml) 33.9G18.5 23.3G12.9 NS
Data are given as means and SDs. NS, not significant.
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Patients undergoing adrenalectomy were slightly more
obese at baseline than those who were not treated with
adrenalectomy, but the difference was not statistically
significant. At the time of follow-up, the BMI was
slightly increased in both groups without any signi-
ficant differences between the two groups. When
compared with baseline, the prevalence of hyperlipide-
mia and the number of patients treated with lipid-
lowering drugs increased significantly at the time of
follow-up in the two groups of patients with and
without adrenalectomy. Plasma total cholesterol
concentrations in both groups showed a significant
decrease at the time of follow-up when compared with
those measured at baseline. There were no statistically
significant differences in the frequency of usage of lipid-
lowering drugs (Table 3) between patients treated and
not treated with adrenalectomy.
When compared with baseline, the prevalence of
T2DM increased, whereas the prevalence of impaired
glucose tolerance decreased significantly during the
follow-up period in patients both with and without
adrenalectomy (Table 3). Surgical removal of the
adrenal adenoma failed to influence the prevalence of
T2DM. At the time of follow-up, there were no
statistically significant differences in the concentrations
of plasma glucose, in the frequencies of usage of
antidiabetic agents (Table 3), between patients treated
and not treated with adrenalectomy.
When compared with the data obtained from a large
cohort representing the Hungarian general population
(31), the prevalences of hypertension and diabetes
mellitus were significantly higher in patients with
NFAAs both at baseline (Table 4) and at the time of
follow-up (Table 5). These prevalences were significantly
increased also in patients treated with surgery when
compared with the general population (data not shown).
The number of various atherosclerotic events, as well
as the number of coronary and peripheral arterial
interventions occurring after the diagnosis of NFAA and
adrenalectomy in the surgical group is presented in
Table 6. No statistically significant differences were
found in the prevalences of these events and interven-
tions between patients treated and not treated with
adrenalectomy. In addition, the cardiovascularwww.eje-online.orgmortality was also similar in the groups of patients
treated and not treated with adrenalectomy.
Thirteen of the 125 patients (10.4%) with NFAAs
qualified for subclinical Cushing’s syndrome, of which
two patients fulfilled both criteria. Midnight plasma
cortisol concentrations but not those measured at
0800 h or after a low-dose dexamethasone test were
significantly higher in patients with subclinical Cush-
ing’s syndrome when compared with those found in
patients without subclinical Cushing’s syndrome
(Table 7). Five of the 13 patients with subclinical
Cushing’s syndrome were treated with surgery. Mean
tumor diameter in all patients with subclinical
Cushing’s syndrome and in those who were operated
on did not differ from that found in patients without
subclinical Cushing’s syndrome. In addition, the
occurrence of metabolic and cardiovascular risk factors
was similar in patients with and without subclinical
Cushing’s syndrome. One of the patients diagnosed
initially with subclinical Cushing’s syndrome developed
suppressed plasma ACTH concentration at follow-up
without any signs and symptoms of hypercortisolism.
No other major changes were detected in any of the
laboratory parameters of these patients at the follow-
up visit. There were no significant differences in any
other laboratory parameters or in the prevalences of
incident vascular events and interventions between
patients with and without subclinical Cushing’s
syndrome (not shown in tables).Discussion
The long-term benefit attained from surgical interven-
tion is one of the most important unresolved issues
regarding the management of patients with incidentally
discovered adrenal tumors. Patients with adrenal
masses causing unambiguous hormonal overactivity
and those with suspected malignancy are clearly
candidates for surgical interventions. Although the
prevalence of metabolic abnormalities and accom-
panying disorders resulting in an increased athero-
sclerotic risk are high among patients with NFAAs and
especially in those causing subclinical hypercortisolism
(15, 16), the cause and effect relationship between
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Table 4 Prevalences of high blood pressure and type 2 diabetes mellitus in patients with non-functioning adrenocortical adenomas at
baseline and in the general Hungarian population.
Patients with non-functioning
adrenocortical adenomas
at baseline General Hungarian population
Difference between patients with
non-functioning adrenocortical
adenoma and general Hungarian
population
Sex Females Males Females Males Females Males
Number of
patients
89 24 23 000 22 079
Mean age of
patients, year
50.8 53.4
Age range, year 45–54 45–54
Number (percent)
of patients with
hypertension
72 (81%) 21 (87%) 6184 (27%) 5877 (27%) P!0.0001 P!0.0001
Number (percent)
of patients with
type 2 diabetes
16 (18%) 7 (29%) 982 (4%) 1595 (7%) P!0.0001 P!0.0001
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not been clearly established.
Our present study, in accordance with other reports
(18), demonstrates that the prevalences of several ARF
are increased in patients with NFAAs. At the time of
diagnosis, the prevalences of hypertension, T2DM,
obesity, and hyperlipidemia in our patients were
comparable with those reported in the majority of
other series (6, 10, 16–18, 21–26, 32). Among several
clinical, biochemical, and hormonal parameters inves-
tigated in our study, adrenal tumor diameter was the
only parameter influencing significantly the decision
between surgical and non-surgical treatment of our
patients with NFAAs.
It is presently unclear how surgical removal of NFAAs
may affect the increased atherosclerotic risk of these
patients. The few follow-up studies of patients with non-
functioning adrenal tumors have been focused on theTable 5 Prevalences of hypertension and type 2 diabetes mellitus
adrenalectomy at the time of follow-up and in the general Hungarian p
Patients with non-functioning
adrenocortical adenomas without
adrenalectomy at the time of
follow-up Genera
Sex Females Males Fema
Number of
patients
53 17 19 7
Mean age of
patients (year)
60.5 63.2
Age range (year) 55–6
Number (percent)
of patients with
hypertension
47 (89%) 16 (94%) 9716 (4
Number (percent)
of patients with
type 2 diabetes
mellitus
25 (47%) 11 (65%) 2082 (1
www.eje-online.orgprevalence of growth of tumor mass or change in
hormonal activity (33–36), but the prevalence of
various cardiovascular events has not been evaluated
in these patients. It has been shown that the
atherosclerotic risk decreases, but not returns to normal
after the cure of overt (28) and subclinical Cushing’s
syndrome (27). However, only a few studies investigated
the postoperative changes in various clinical and
metabolic parameters reflecting atherosclerotic risk in
patients with non-functioning adrenal tumors (18, 22).
Insulin resistance has been shown to be improved in
some, but not all patients after unilateral adrenalectomy
in patients with non-functioning adrenal tumors
including those presenting with subclinical hypercorti-
solism (21).
When comparing patients with and without adrena-
lectomy, detailed investigations of various plasma
lipoprotein fractions, basal plasma glucose, serumin patients with non-functioning adrenocortical adenomas without
opulation.
l Hungarian population
Difference between patients with
non-functioning adrenocortical
adenomas without adrenalectomy
at the time of follow-up and general
Hungarian population
les Males Females Males
99 16 691
4 55–64
9%) 7414 (44%) P!0.0001 P!0.0001
1%) 2347 (14%) P!0.0001 P!0.0001
Table 6 Cardiovascular/cerebrovascular morbidity and mortality at the time of follow-up in patients with non-functioning adrenocortical
adenomas treated and not treated with adrenalectomy.
Patients with
adrenalectomy
(nZ47)
Patients without
adrenalectomy
(nZ78)
Difference between
patients with and without
adrenalectomy (P value)
Number (percent) of patients with
cardiovascular morbidity
16 (34%) 25 (32%) 0.8
Number (percent) of major
cardiovascular events
9 (19%) 13 (17%) 0.7
Number (percent) of patients with
angina pectoris
7 (15%) 9 (12%) 0.58
Number (percent) of patients with
acute myocardial infarction
2 (4%) 9 (12%) 0.16
Number (percent) of
cardiovascular mortality
2 (4%) 3 (4%) 0.9
Number (percent) of patients with
coronary interventions
1 (2%) 6 (8%) 0.2
Number (percent) of patients with
percutaneous transluminal coronary
angioplasty
1 (2%) 3 (4%) 0.6
Number (percent) of patients with
coronary bypass surgery
0 4 (5%) 0.1
Number (percent) of intervention for
peripheral arterial stenosis/occlusion
7 (15%) 5 (6%) 0.1
Number (percent) of patients with
cerebrovascular stroke
7 (15%) 12 (15%) 0.9
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any metabolic benefit from the surgical removal of
NFAAs. This finding was in accordance with the lack of
differences in the prevalences of cardiovascular adverse
events and vascular interventions between patients
with and without adrenalectomy. Among several
parameters investigated in the present study, plasma
total cholesterol was the only ARF, which showed a
decrease at the time of follow-up, but this change proved
to be independent of adrenal surgery and could be
related to the more frequent usage of lipid-lowering
agents, especially statins, at the time of follow-up.
To our best knowledge, this is the first study in
patients with NFAAs, which investigated not only theTable 7 Baseline hormonal findings in patients with non-functioning
adrenocortical adenomas with and without subclinical Cushing’s
syndrome.
Patients
without
SCS
Patients
with SCS
Difference
between
patients with
and without
SCS
Midnight plasma
cortisol (mg/dl)
2.4G1.4 6.0G3.9 !0.05
Morning plasma
cortisol (mg/dl)
10.4G5.2 11.6G5.1 NS
Plasma cortisol
after low-dose
DXM (mg/dl)
1.8G0.7 3.1G3.0 NS
Plasma ACTH
(pg/ml)
26.1G16.8 21.2G14.7 NS
Data are given as means and SDs. SCS, subclinical Cushing’s syndrome;
NS, not significant.baseline atherosclerotic risk profile and its short-term
change after adrenalectomy, but also the prevalence of
long-term adverse cardiovascular events. Most impor-
tantly, our results indicate that despite the highly
increased atherosclerotic risk parameters, surgical
removal of the non-functioning adrenal adenoma failed
to lower the prevalence of various adverse vascular
events.
Our present study has some important limitations
which should be taken into account. It is important to
note that the prevalence of hypertension in our
patients with NFAA was very high even at baseline
(80%). The most probable explanation for this
observation is that in several cases, ultrasonography
or computer tomography were performed preferably in
hypertensive patients to search for secondary causes of
high blood pressure. The relatively low number of
patients, especially the low number of patients with
subclinical Cushing’s syndrome represents another
important limitation of our study. However, the long
follow-up period should be considered as a strength of
the study which may, at least partially, compensate for
the relatively small patient cohort. Further limitations
are the retrospective nature of this study and the lack
of usage of standardized drug treatment protocol.
However, the medical treatment of the patients during
the follow-up period was managed mainly by the
patients’ general practitioners according to the
general treatment practices. Our analysis revealed an
absence of significant differences in the usage of
various drug treatments between patients treated and
not treated with adrenalectomy. Nevertheless, we
cannot exclude the possibility of minor differences,www.eje-online.org
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treatments or in the compliance of these patients.
Our observations support the possibility that the
association between NFAAs and the high prevalence of
adverse atherosclerotic risk profile does not necessarily
reflect a cause and effect relationship, as these metabolic
abnormalities may persist for a long period of time after
surgical removal of the NFAAs. It is possible that the
lack of improvement of adverse atherosclerotic risk
profile after adrenal surgery may be the consequence of
persisting abdominal obesity and insulin resistance,
similar to those observed during a long-term follow-up
of patients after curative surgery for pituitary Cushing’s
disease (28).
In conclusion, our results clearly indicate that
adrenalectomy performed in patients with non-func-
tioning adrenocortical adenomas failed to normalize or
improve the adverse metabolic profile and the increased
prevalence of hypertension, T2DM, dyslipidemia, and
obesity during a 9-year period of postoperative follow-
up. Adrenalectomy in these patients did not result in a
decrease of atherosclerotic morbidity and mortality.
Nevertheless, a large prospective, randomized study
may be needed to explore more definitively the long-
term outcome of adrenalectomy on adverse metabolic
profile as well as on atherosclerotic mortality and
morbidity in these patients. This prospective trial should
focus also on the differences in the long-term con-
sequences of adrenocortical adenomas with and with-
out the laboratory abnormalities of subclinical
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